Moderna to Pay Up to $2.25B to Settle COVID Vaccine Patent Dispute

Moderna reaches deal with Genevant Sciences and Arbutus Biopharma over lipid nanoparticle technology used in its COVID-19 vaccine.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Moderna has agreed to pay up to $2.25 billion to settle a long-running legal dispute with Genevant Sciences and Arbutus Biopharma over the lipid nanoparticle (LNP) technology used in Moderna's COVID-19 vaccine. The deal resolves all U.S. and international legal actions accusing Moderna of using the LNP delivery technology without permission.

Why it matters

The settlement removes a major legal risk for Moderna, eliminating the potential for double-digit royalty payments on its COVID-19 vaccine sales, which have totaled around $48 billion globally. It also clears the way for Moderna to develop future COVID and COVID/flu combination vaccines without royalty concerns.

The details

Under the deal, Moderna will pay $950 million upfront in July 2026, with an additional $1.3 billion that depends on the outcome of a separate legal appeal. The agreement resolves all patent infringement allegations from Genevant and Arbutus, and Moderna will not owe the companies any royalties for using the LNP technology in its future vaccines.

  • Moderna will pay the $950 million upfront in July 2026.
  • The additional $1.3 billion payment depends on the outcome of a separate legal appeal.

The players

Moderna

An American biotechnology company that developed one of the first COVID-19 vaccines authorized for use.

Genevant Sciences

A subsidiary of Roivant Sciences that owns the lipid nanoparticle (LNP) delivery technology used in Moderna's COVID-19 vaccine.

Arbutus Biopharma

A biopharmaceutical company that co-owns the LNP technology with Genevant Sciences.

Got photos? Submit your photos here. ›

What they’re saying

“The settlement 'removes the worst-case scenario' of potentially double-digit royalty rates, and it also eliminates any future royalty risk for Moderna's upcoming COVID and COVID/flu combo vaccines.”

— Andrew Tsai, Jefferies analyst (Claims Journal)

What’s next

The deal resolves all outstanding legal disputes between the parties, clearing the way for Moderna to continue developing its COVID-19 and combination vaccine products without further patent concerns.

The takeaway

This settlement represents a pragmatic resolution to a high-stakes legal battle over the key technology enabling Moderna's highly successful COVID-19 vaccine. It removes a major financial overhang for the company and allows it to focus on advancing its vaccine pipeline without the uncertainty of potential royalty payments.